Abstract: Methods for preparing a catalyst precursor material from dihalo-substituted metalloids are provided. The methods In include mixing a first solution of a halogenated alkane, at least one solvent, and a first component selected from a dihalo-substituted-group-14 metalloid or an organolithium reagent in a first reaction zone. Continuously adding the first solution to a second reaction zone, and continuously adding a second solution to the second reaction zone. The second solution including at least one solvent and a second component of either the dihalo-substituted-group-14 metalloid or the organolithium reagent, the second component is different from the first component. Mixing the first solution and the second solution in the second reaction zone.

Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.

Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.

Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.